LifePort Liver Transporter has not been cleared or approved by FDA, and the safety and effectiveness of the LifePort Liver Transporter has not been established. LifePort Liver Transporter is not available for sale within the United States.
Panayotova et al. published a multicenter, randomized, noninferiority trial which sought to compare liver preservation using the LifePort Liver Transporter to the standard of care, static cold storage. The study included 142 liver transplant procedures from 9 US centers, and compared outcomes such as early allograft dysfunction, L-GrAFT7 score, primary nonfunction, biliary strictures, and non-anastomotic biliary strictures.
They found that:
- Lower incidence of EAD in HMP-O2
- Risk of graft failure as predicted by L-GrAFT7 was lower in HMP-O2
- Lower incidence of PNF in HMP-O2
- Lower incidence of biliary strictures in HMP-O2
- Severe non-infectious adverse events were almost 3x more common in SCS
Read the full article here: https://journals.lww.com/hep/abstract/9900/portable_hypothermic_oxygenated_machine_perfusion.678.aspx
The Latest
